eligibility_summary
Adults 18–70 with unresectable/metastatic ESCC, ≥1 RECIST measurable lesion, tumor tissue, ECOG 0–1, life ≥12 wks, adequate organs, use contraception. Exclude: uncontrolled CNS mets/pain, significant effusions/ascites, recent GI perforation/fistula risk, recent surgery/RT/systemic therapy, prior topo‑I ADC, strong CYP/P‑gp/BCRP meds, live vaccine/immunosupp., ILD, serious CV/CVA, recent thrombosis, other cancer, severe infection, active HBV/HCV/TB, immunodeficiency, severe allergy, major blood loss.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial drugs/interventions and mechanisms: - SHR-A2102: investigational antibody–drug conjugate (ADC) carrying a topoisomerase I inhibitor payload, binds a tumor cell–surface antigen (specific target not stated in the record) to deliver the cytotoxin intracellularly, causing DNA single-strand breaks/replication stress and tumor-cell apoptosis (possible bystander effect). - Adebrelimab (SHR-1316): anti–PD-L1 IgG1 monoclonal antibody immune checkpoint inhibitor, blocks PD-L1 interaction with PD-1/CD80 to restore T-cell antitumor activity. - Cisplatin: platinum chemotherapeutic, forms DNA crosslinks leading to apoptosis. Cells/pathways targeted: antigen-expressing tumor cells via the ADC, DNA replication/repair pathways via topoisomerase I inhibition and platinum crosslinking, PD-1/PD-L1 immune checkpoint on tumor/immune cells to activate cytotoxic T cells.